Skip to Content
UW Health SMPH
American Family Children's Hospital
DONATE Donate
SHARE TEXT

PAR-13-327 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44)

PAR-13-327 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44)

 

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

 

Application Due Dates: November 4, 2013; May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016